Next Article in Journal
Recent Progress of Chitosan and Chitosan Derivatives-Based Nanoparticles: Pharmaceutical Perspectives of Oral Insulin Delivery
Next Article in Special Issue
Brain-Targeted Delivery of Pre-miR-29b Using Lactoferrin-Stearic Acid-Modified-Chitosan/Polyethyleneimine Polyplexes
Previous Article in Journal
Prediction of Antidepressant Treatment Response and Remission Using an Ensemble Machine Learning Framework
Previous Article in Special Issue
Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer’s Disease
Open AccessReview

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?

1
College of Health and Biomedicine, Victoria University, Melbourne, VIC 8001, Australia
2
Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia
3
Australian Institute for Musculoskeletal Science, Victoria University, St Albans, VIC 3021, Australia
4
Oxidative Stress Laboratory, Baker Heart and Diabetes Institute, Basic Science Domain, Melbourne, VIC 3004, Australia
5
Department of Physiology, Anatomy and Microbiology, La Trobe University, Melbourne, VIC 3083, Australia
6
School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7005, Australia
7
Division of Developmental- and Neuropediatrics, University Children’s Hospital Basel, University of Basel, 4056 Basel, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(10), 306; https://doi.org/10.3390/ph13100306
Received: 27 September 2020 / Revised: 8 October 2020 / Accepted: 12 October 2020 / Published: 13 October 2020
(This article belongs to the Special Issue Therapeutic Agents for Neurological Disorders)
Fumaric acid esters (FAEs) are small molecules with anti-oxidative, anti-inflammatory and immune-modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing-Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune-mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first-line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated. View Full-Text
Keywords: clinical application; dimethyl fumarate; disease; fumaric acid esters; oxidative stress; inflammation; Nrf2; disease clinical application; dimethyl fumarate; disease; fumaric acid esters; oxidative stress; inflammation; Nrf2; disease
Show Figures

Figure 1

MDPI and ACS Style

Kourakis, S.; Timpani, C.A.; de Haan, J.B.; Gueven, N.; Fischer, D.; Rybalka, E. Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility? Pharmaceuticals 2020, 13, 306.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop